SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Silk Road Inc. (Nasdaq – SILK)

BALA CYNWYD – June 18, 2024 /Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Silk Road Medical, Inc. (“Silk Road” or the “Company”) (Nasdaq – SILK) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Boston Scientific Corporation (“Boston Scientific”) (NYSE – BSX). Under the terms of the agreement, Boston Scientific will acquire all outstanding shares of Silk Road common stock for $27.50 per share in cash, for an equity value of $1.26 billion.

The investigation concerns whether the Silk Road Group Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Boston Scientific is paying fair value to shareholders of the Company. For example, the deal consideration is below the 52-week high of $34.13 for the Company’s shares.

If you own shares of Silk Road Group stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at clients@brodsky-smith.com, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.